CRTC2 and acute lymphoblastic leukemia: Like the earlier TORC1/TORC2 inhibitor OSI‐027, sapanisertib exhibited greater cytotoxic effects than rapamycin in multiple human ALL lines and in clinical ALL samples treated ex vivo.29